Opioid switch to oral methadone in cancer pain
by
Mancini I, Lossignol DA, Body JJ
Supportive and Palliative Care Unit,
Institut Jules Bordet,
Brussels,
Belgium.
sans.palliative@bordet.br
Curr Opin Oncol 2000 Jul; 12(4):308-13

ABSTRACT

Mhe occurrence of undesirable side effects due to opioids (delirium, confusion, myoclonus, nausea, emesis) is one of the major complications in the management of pain, especially in chronic cancer pain states. Methadone, as an alternative to morphine, has been proposed in the control of opioid-induced toxicity. Methadone is a synthetic opioid, with mu and delta receptor activity, associated with the capacity to inhibit N-methyl-D-aspartate receptors. Questions have arisen concerning its equianalgesic ratio since its rediscovery over the past few years and are certainly related to its receptor interactions. Aspects of its pharmacology, indications, and switching modalities are discussed here. Opioid rotation is a new tool in the management of cancer pain, deserving more attention.

Pain
LAAM
Arousal
Fentanyl
Tramadol
Tolerance
Nociceptin
Remifentanil
Endomorphins
OTC cough syrups
LAAM v methadone
Methadone: structure
Opioids and depression
Methadone and cocaine
Methadone maintenance
Rapid opioid detoxification
Methadone and cancer pain

Refs
HOME
HedWeb
cannabis-marijuana.com
BLTC Research
Paradise-Engineering
The Hedonistic Imperative
When Is It Best to Take Crack Cocaine?